Each person’s cancer is unique. The treatment journey should be too.

Cancer has a devastating impact on those living with the disease and their loved ones, and oncologists face major challenges as they work to deliver effective care tailored to each patient. On average, 75% of cancer patients will not respond to a particular drug in a class of agents. It’s no wonder that oncologists are increasingly looking to genomics insights to identify more precise and potentially effective therapies.

Cancer genomics and cognitive computing: Bending the analysis curve

At IBM Watson Health, we believe that the future of cancer care lies within precision medicine. Interested in what the possibilities are when this is paired with cognitive computing?

Product Key Features

Information to help enhance clinical confidence

The Molecular Profile highlights the most likely driver mutation and the type of alteration. Additionally, you can hover over each mutation to get more information

Information regarding potentially actionable therapeutic options

The summary page provides an overview of the actionable gene alterations, potential treatments, and additional clinical trials, before the report delves into each category in much greater detail.

Information to help enhance confidence

In addition to providing information regarding your tumor’s genetic alterations, Watson for Genomics also draws evidence from a vast corpus of medical literature, as well as MSK’s OncoKB, a precision oncology knowledge base. A comparison that may typically take a team of medical experts weeks to prepare can now be completed in significantly less time. This can help clinicians and their patients and cancer care teams feel more confident about the path forward with an evidence-based, individualized care plan.

Watson is helping cancer care teams around the world implement a more patient-centric cancer care model.

IBM Watson Health Partners


Quest Diagnostic is partnering their genomic sequencing services with Watson for Genomics to help physicians bring precision cancer treatments to patients nationwide. Quest Diagnostic serves half the nation’s physicians and hospitals, and is now extending these advanced capabilities to thousands of the country’s community oncologists, who provide an estimated 70% of cancer care in the United States.

New York Genome Center

The New York Genome Center conducted a study demonstrating the potential for AI and whole genome sequencing to scale access to precision medicine. They concluded that the development of an effective human-machine interface in the analysis of complex cancer genomic data sets may identify potential therapies for individual patients in a more timely and efficient manner than currently possible.

The latest from Watson Health